Accepted Manuscript



Invited Editorial: Advantages and Limitations of FAERS in Assessing Adverse Event Reporting for Eluxadoline

Victor Chedid, M.D., Priya Vijayvargiya, M.D., Michael Camilleri, M.D.

PII: S1542-3565(17)31362-9
DOI: 10.1016/j.cgh.2017.11.025
Reference: YJCGH 55559

To appear in: *Clinical Gastroenterology and Hepatology*
Accepted Date: 11 November 2017

Please cite this article as: Chedid V, Vijayvargiya P, Camilleri M, Invited Editorial: Advantages and Limitations of FAERS in Assessing Adverse Event Reporting for Eluxadoline, *Clinical Gastroenterology and Hepatology* (2017), doi: 10.1016/j.cgh.2017.11.025.

gim/c/c/man/CGH_Editorial_eluxadoline_11_7_17_Fasiha_CLEAN.docx
11-7-17
For resubmission to CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

Invited Editorial: Advantages and Limitations of FAERS in Assessing Adverse Event Reporting for Eluxadoline

Victor Chedid, M.D.*
Priya Vijayvargiya, M.D.*
Michael Camilleri, M.D.
(*co-first authors)

From
Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER)
Mayo Clinic, Rochester, MN

Word count: 1317 words (not including references)

Short title: FAERS analysis of eluxadoline-induced pancreatitis

Abbreviations:
AE – Adverse events
ADR – adverse drug reaction
FAERS – federal adverse events reporting system
FDA – food and drug administration
IBS – irritable bowel syndrome
IBS-D – irritable bowel syndrome – diarrhea predominant
MEDRA - Medical Dictionary for Regulatory Activities
OR – opioid receptor
SAE – serious adverse events
SOD – sphincter of Oddi dysfunction

Disclosures: The authors have no conflicts of interest.

Authors' contributions:
Victor Chedid - research fellow, authorship of manuscript
Priya Vijayvargiya - research fellow, authorship of manuscript
Michael Camilleri - senior author, conceptualizing and revising manuscript

Acknowledgement: The authors thank Mrs. Cindy Stanislav for excellent secretarial assistance.

Funding support: Dr. Camilleri receives support from National Institutes of Health grant R01-DK67071.

Corresponding author: Michael Camilleri, M.D.
Mayo Clinic
200 First St. S.W.
Charlton Bldg., Rm. 8-110
Rochester, MN 55905
Tel: 507-266-2305
email: camilleri.michael@mayo.edu